肾移植术后骨病的自然史
本研究为前瞻性观察性队列研究,纳入97例接受保类固醇免疫抑制方案的肾移植患者,在移植前及移植后12个月进行骨表型评估。结果显示多数患者骨转换正常或改善,骨吸收指标下降,但15%患者出现矿化延迟,且低磷血症与矿化参数恶化相关;骨密度变化个体差异大,类固醇累积剂量与髋部骨丢失相关,甲状旁腺功能亢进缓解与脊柱和髋部骨获得相关。
要点
- 肾移植后多数患者骨转换正常或改善,骨吸收和纤维化减少。
- 移植后1年15%患者出现矿化延迟,低磷血症与矿化参数恶化相关。
- 骨密度变化个体差异大,类固醇累积剂量与髋部骨丢失相关。
核心结论
- 肾移植后骨转换、矿化和体积的变化与类固醇暴露和持续的矿物质代谢紊乱相关,最佳控制矿物质代谢可能是改善移植受者骨质量的关键。
研究设计与样本
- 前瞻性观察性队列研究,纳入97例接受保类固醇免疫抑制方案的肾移植患者,在移植前或移植时及移植后12个月进行骨表型评估。
主要发现
- 骨转换在多数患者(65%)保持正常或改善。
- 骨吸收指标(侵蚀周长)均值从移植前4.6%降至移植后2.3%(P<0.001),骨形成障碍(纤维化)从移植前27%降至移植后2%(P<0.001)。
- 移植前除1例患者外骨矿化均正常,移植后1年15%患者出现矿化延迟。
- 低磷血症与骨矿化组织形态学参数恶化相关。
- 骨密度变化高度可变,范围为每年-18%至+17%;类固醇累积剂量与髋部骨丢失相关,甲状旁腺功能亢进缓解与脊柱和髋部骨获得相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Knowledge of the effect of kidney transplantation on bone is limited and fragmentary. The aim of this study was to characterize the evolution of bone disease in the first post-transplant year. METHODS: We performed a prospective, observational cohort study in patients referred for kidney transplantation under a steroid-sparing immunosuppressive protocol. Bone phenotyping was done before, or at the time of, kidney transplantation, and repeated at 12 months post-transplant. The phenotyping included bone histomorphometry, bone densitometry by dual-energy x-ray absorptiometry, and biochemical parameters of bone and mineral metabolism. RESULTS: Paired data were obtained for 97 patients (median age 55 years; 72% male; 21% of patients had diabetes). Bone turnover remained normal or improved in the majority of patients (65%). Bone histomorphometry revealed decreases in bone resorption (eroded perimeter, mean 4.6% pre- to 2.3% post-transplant; P<0.001) and disordered bone formation (fibrosis, 27% pre- versus 2% post-transplant; P<0.001). Whereas bone mineralization was normal in all but one patient pretransplant, delayed mineralization was seen in 15% of patients at 1 year post-transplant. Hypophosphatemia was associated with deterioration in histomorphometric parameters of bone mineralization. Changes in bone mineral density were highly variable, ranging from -18% to +17% per year. Cumulative steroid dose was related to bone loss at the hip, whereas resolution of hyperparathyroidism was related to bone gain at both spine and hip. CONCLUSIONS: Changes in bone turnover, mineralization, and volume post-transplant are related both to steroid exposure and ongoing disturbances of mineral metabolism. Optimal control of mineral metabolism may be key to improving bone quality in kidney transplant recipients. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evolution of Bone Histomorphometry and Vascular Calcification Before and After Renal Transplantation, NCT01886950.
引用
- Jørgensen HS, Behets G, Bammens B, et al. Natural History of Bone Disease following Kidney Transplantation. J Am Soc Nephrol. 2022. PMID: 35046132. doi:10.1681/ASN.2021081081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。